Scientific Reports (Oct 2021)

Treatment for COVID-19—a cohort study from Northern Italy

  • Lorenzo Guglielmetti,
  • Daniela Aschieri,
  • Irina Kontsevaya,
  • Francesco Calabrese,
  • Alessandra Donisi,
  • Alberto Faggi,
  • Patrizia Ferrante,
  • Elisa Fronti,
  • Laura Gerna,
  • Maria Cristina Leoni,
  • Franco Paolillo,
  • Giovanna Ratti,
  • Alessandro Ruggieri,
  • Daria Sacchini,
  • Marta Scotti,
  • Caterina Valdatta,
  • Marco Stabile,
  • Gloria Taliani,
  • Mauro Codeluppi

DOI
https://doi.org/10.1038/s41598-021-00243-4
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of tocilizumab and of high doses of low molecular weight heparin, but not of antivirals (either alone or in combination), azithromycin, and any corticosteroid, was independently associated with lower mortality. Our results support further clinical evaluation of high doses of low molecular weight heparin and tocilizumab as COVID-19 therapeutics.